Refanezumab

From Food & Medicine Encyclopedia

Refanezumab is a monoclonal antibody designed for the treatment of migraine. It is developed by Teva Pharmaceuticals and is currently in the clinical trial phase. Refanezumab works by blocking the calcitonin gene-related peptide receptor (CGRP), a protein that plays a key role in migraine attacks.

Mechanism of Action[edit]

Refanezumab is a monoclonal antibody that targets and blocks the CGRP receptor. CGRP is a neuropeptide that is released during a migraine attack and is believed to play a key role in the transmission of pain. By blocking the CGRP receptor, refanezumab prevents the activation of this pathway and reduces the frequency and severity of migraine attacks.

Clinical Trials[edit]

Refanezumab is currently in Phase III clinical trials. In a Phase IIb study, refanezumab demonstrated a significant reduction in the number of migraine days per month compared to placebo. The most common side effects reported were injection site reactions.

Development[edit]

Refanezumab is being developed by Teva Pharmaceuticals, a global pharmaceutical company specializing in the development, production, and marketing of generic and proprietary branded pharmaceuticals.

See Also[edit]

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Refanezumab&oldid=5296160"